Ventilator-Associated Pneumonia in Patients with COVID-19: A Systematic Review and Meta-Analysis.
Mariachiara IppolitoGiovanni MisseriGiulia CatalisanoClaudia MarinoGiulia IngogliaMarta AlessiElisa ConsiglioCesare GregorettiAntonino GiarratanoAntonino GiarratanoPublished in: Antibiotics (Basel, Switzerland) (2021)
The aim of this systematic review and meta-analysis was to estimate the pooled occurrence of ventilator-associated pneumonia (VAP) among patients admitted to an intensive care unit with COVID-19 and mortality of those who developed VAP. We performed a systematic search on PubMed, EMBASE and Web of Science from inception to 2nd March 2021 for nonrandomized studies specifically addressing VAP in adult patients with COVID-19 and reporting data on at least one primary outcome of interest. Random effect single-arm meta-analysis was performed for the occurrence of VAP and mortality (at the longest follow up) and ICU length of stay. Twenty studies were included in the systematic review and meta-analysis, for a total of 2611 patients with at least one episode of VAP. The pooled estimated occurrence of VAP was of 45.4% (95% C.I. 37.8-53.2%; 2611/5593 patients; I2 = 96%). The pooled estimated occurrence of mortality was 42.7% (95% C.I. 34-51.7%; 371/946 patients; I2 = 82%). The estimated summary estimated metric mean ICU LOS was 28.58 days (95% C.I. 21.4-35.8; I2 = 98%). Sensitivity analysis showed that patients with COVID-19 may have a higher risk of developing VAP than patients without COVID-19 (OR 3.24; 95% C.I. 2.2-4.7; P = 0.015; I2 = 67.7%; five studies with a comparison group).
Keyphrases
- end stage renal disease
- intensive care unit
- chronic kidney disease
- ejection fraction
- newly diagnosed
- systematic review
- risk assessment
- sars cov
- peritoneal dialysis
- risk factors
- type diabetes
- public health
- machine learning
- mechanical ventilation
- coronary artery disease
- meta analyses
- study protocol
- adverse drug
- respiratory failure